A preservative free generic alternative to DuoNeb® (Ipratropium Bromide Bar Coded; Available in the following package configurations per box. Mylan Specialty: DuoNeb is indicated for the treatment of bronchospasm associated with COPD in patients requiring more than one. Prescription Drug Information: Duoneb. Ritedose Pharmaceuticals DUONEB- ipratropium bromide and albuterol sulfate solution. Ritedose.

Author: Fesida Gardalkis
Country: Dominican Republic
Language: English (Spanish)
Genre: History
Published (Last): 23 October 2005
Pages: 477
PDF File Size: 8.78 Mb
ePub File Size: 16.79 Mb
ISBN: 194-7-28794-116-4
Downloads: 74560
Price: Free* [*Free Regsitration Required]
Uploader: Zulumi

Post-marketing surveillance for lomefloxacin has identified very rare cases of torsade de pointes TdP.

PDR Search

According to the manufacturer, since iloperidone may prolong the QT interval, it should be avoided in combination with other agents also known to have this effect. Patients must avoid exposing their eyes to this product as temporary papillary dilation, inssrt vision, eye pain, or precipitation or worsening of narrow-angle glaucoma may occur, and therefore proper nebulizer technique should be assured, particularly if a mask is used.

Minor Use caution with coadministration of hydroxychloroquine and short-acting beta-agonists. Beta-agonists can sometimes increase heart rate or have other cardiovascular effects, particularly when used in high doses or if hypokalemia is present.

Minor Beta-agonists should be used cautiously and with close monitoring with arsenic trioxide. Recipient’s Email Separate multiple email address with a comma Please enter valid email address Recipient’s email is required.

Bedaquiline has been reported to prolong the QT interval. djoneb

Minor Eribulin has been associated with QT prolongation. Minor The need to coadminister methadone with drugs known to prolong the QT interval should be done with extreme caution and a careful assessment of treatment risks versus benefits.

Proarrhythmic events should be anticipated after initiation of therapy and after each upward dosage adjustment. Sit in a comfortable, upright position; place the mouthpiece in your mouth Figure 3 or put on the face mask Figure 4 ; and turn on the compressor.

IPRATROPIUM BROMIDE and ALBUTEROL SULFATE Inhalation Solution (DuoNeb) 05 mg30 mg | Mylan

Minor Use these drugs together with caution. Minor Some quinolones, including ofloxacin, have been associated with QT prolongation and infrequent cases of arrhythmia.


If vemurafenib and another drug that is associated with a possible risk for QT prolongation and torsade de pointes TdP must be coadministered, ECG monitoring is recommended; closely monitor the patient for QT interval prolongation.

Moderate Linezolid may enhance the hypertensive effect of beta-agonists. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. Care should be taken not to spray albuterol; ipratropium in the eyes. Minor Hypokalemia associated with thiazide diuretics can be acutely worsened by beta-agonists, especially when pac,age recommended dose of the beta-agonist is exceeded.

To avoid the spread of infection, do not use the inhaler spray for more than one person. In clinical trials, QT prolongation was reported in patients who received iinsert as single-agent therapy or in combination with cytarabine and daunorubicin. Drugs with a possible risk for QT prolongation and TdP that should be used cautiously and with close monitoring with romidepsin include the beta-agonists. Drugs with a possible risk for QT prolongation and torsade de pointes TdP that should be used cautiously and with close monitoring with granisetron include the beta-agonists.

Mylan Worldwide

Droperidol administration is associated with an established risk for QT prolongation and torsade de pointes TdP. Post-marketing surveillance has identified very rare cases of ventricular arrhythmias including torsade de pointes TdPusually in patients with severe underlying proarrhythmic conditions. Weigh the risks of co-use, and where possible, allow a washout period after discontinuation of the MAOI before instituring beta-agonist treatment or vice-versa.

Moderate Although ipratropium is minimally absorbed into the systemic circulation after inhalation, there is the potential for additive anticholinergic effects when administered with other antimuscarinic or anticholinergic medications.

Crizotinib has been associated with concentration-dependent QT prolongation. Moderate Beta-agonists are commonly used in conjunction with aminophylline or theophylline therapy. Minor Rare cases of QT prolongation and torsade de pointe TdP have been reported with ciprofloxacin during post-marketing surveillance.


The safety and efficacy of DuoNeb delivered by other nebulizers and compressors have not been established. The mouthpiece, including the metal part inside the mouthpiece, should be cleaned with a damp cloth or tissue only, at least 1 time a week; any minor discoloration in the mouthpiece does not affect the inhaler.

Clinically relevant QTc prolongation may occur with deutetrabenazine. The manufacturer of ezogabine recommends packabe during concurrent use of medications known to increase the QT interval. Albuterol is a moderately selective beta2-adrenergic agonist that stimulates receptors of the smooth muscle in the lungs, uterus, and vasculature supplying skeletal muscle.

Post-marketing surveillance for ofloxacin has identified very rare cases of torsade de pointes TdP.

Albuterol can also inhibit the degranulation and subsequent release of inflammatory autocoids from mast cells. Inhaled combination of a short-acting beta agonist SABAalbuterol, with a short-acting antimuscarinic agent, ipratropium Primarily used in the treatment of COPD in adults, also used off-label for the acute management of asthma in adult and pediatric ibsert Available as oral inhalation or nebulizer solution; combination therapy produces a greater effect than either drug alone.

The increase in QTc is approximately 10 milliseconds at doses of mg twice daily the FDA-approved dose and up to 25 milliseconds at doses of mg twice daily. Minor Insery of ivosidenib with short-acting beta-agonists may increase the risk of QT prolongation. Therefore, caution is advised when administering olanzapine with drugs having an established causal association with QT prolongation.

Beta-agonists and beta-blockers are pharmacologic opposites, and will counteract each other to some extent when given concomitantly, especially when non-cardioselective beta blockers are used. Additional doses and increased frequency of administration beyond these guidelines have not been studied.

Up to 2 additional 3-mL doses may be allowed per day, if needed.